Locally advanced esophageal squamous cell carcinoma
Conditions
Interventions
Control Group:Standard Radiotherapy Target Delineation + Standard Chemoimmunotherapy
Experimental Group:Individualized Radiotherapy Target Delineation + Standard Chemoimmunotherapy
Sponsors
Harbin Medical University Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Patients with histologically or cytologically confirmed esophageal squamous cell carcinoma; According to the 2017 8th edition AJCC staging system, the patients were in advanced stage. (2) Age 18-75 years, KPS score >=80, weight loss =1L; (6) Blood routine: neutrophil count >=1.5×10^9/L, hemoglobin >=100g/L, platelet count >=100×10^9/L; (7) Renal function: serum creatinine <=1.5 times upper limit of normal; (8) Liver function: aspartate aminotransferase and alanine aminotransferase <=2.5 times the upper limit of normal, bilirubin <=1.5 times the upper limit of normal; (9) Fully understand the study, have the ability to complete the treatment, and have the conditions for follow-up (10) Informed consent was signed voluntarily.
Exclusion criteria
Exclusion criteria: (1) History of other malignancies (previous or concurrent), excluding curable non-melanoma skin cancer, cervical carcinoma in situ, and early papillary thyroid carcinoma; (2) Uncontrolled heart disease or myocardial infarction within the past 6 months; (3) Patients with a history of mental illness; (4) Pregnant and lactating patients; (5) Patients with uncontrolled diabetes and hypertension; (6) Interstitial pneumonia or active pulmonary fibrosis; (7) Active infection; (8) Other conditions deemed unsuitable for enrollment by the responsible physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1-Year Local Control Rate;1-Year Severe Toxicity-Free Survival Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pattern of Treatment Failure;1-Year Overall Survival Rate;Acute and Late Treatment-Related Toxicities;1-Year Progression-Free Survival Rate; | — |
Countries
China
Contacts
Public ContactHang Yin
Harbin Medical University Cancer Hospital
Outcome results
None listed